Depression
Pipeline by Development Stage
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (3)
Approved therapies currently available
Competitive Landscape
62 companies ranked by most advanced pipeline stage
+32 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 11,504 patients across 50 trials
MYnd Analytics Directed Therapy in Depression
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients
Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder
Lithium and Standard Therapy in Resistant Depression
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
Cymbalta for Depression as a Complication of Bereavement
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects
Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
Somatosensory Processing in Depression
BDNF Gene Polymorphism and Antidepressants Treatment
Duloxetine Treatment in Elderly With Dysthymia
Medications for the Treatment of Dysthymic Disorder and Double Depression
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
Beta-CIT-SPECT and Neurophysiology in Depression
DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome
Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission
Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
Can Additional Drug Therapy Accelerate Response Time to Antidepressants
Duloxetine vs. Active Comparator in the Treatment of Patients With Depression
Duloxetine vs. Active Comparator for the Treatment of Depression
Effectiveness of Supplemental Calcium in Preventing Postpartum Depression
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
Physiologic Monitoring of Antidepressant Treatment Response
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
Vortioxetine to Prevent Return of Symptoms in Children With Depression
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
A Trial of AXS-05 in Patients With Major Depressive Disorder
Understanding How Anaesthesia Affects ECT Outcomes
Buprenorphine for Treatment Resistant Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Liothyronine (T3) for Bipolar Depression
Omega-3 Fatty Acids for Treatment of Depression in Adolescents
Memory Functioning and Antidepressant Treatment
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
Study Evaluating Effexor XR for Major Depression.
Study Evaluating Effexor XR in Elderly Patients With Major Depression.
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers
Transcranial Direct Current Stimulation (tDCS) as an add-on Therapy for Treatment of Major Depressive Disorder. (DEPTDCS2014)
Related Jobs in Neurology
Marketing Trainee
Psychatrist/PMHNP - TMS and Spravato Therapy
Senior Manager, HCP Marketing
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Director, Human Resources
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.